Prostate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer

BJU Int. 2017 Sep;120(3):310-312. doi: 10.1111/bju.13871. Epub 2017 May 2.

Authors

John A Violet¹, Michael S Hofman²

Affiliations

¹ Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
² Department of Nuclear Medicine and Molecular imaging, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.

PMID: 28380282
DOI: 10.1111/bju.13871

No abstract available

Publication types

Letter
Review

MeSH terms

Aged
Aged, 80 and over
Biomarkers, Tumor / blood*
Humans
Male
Middle Aged
Molecular Targeted Therapy / methods
Positron Emission Tomography Computed Tomography / methods
Prognosis
Prostate-Specific Antigen / blood
Prostate-Specific Antigen / radiation effects*
Prostatic Neoplasms / blood
Prostatic Neoplasms / diagnostic imaging
Prostatic Neoplasms / radiotherapy*
Radioisotopes / therapeutic use*
Treatment Outcome

Substances

Biomarkers, Tumor
Radioisotopes
Prostate-Specific Antigen